New ALITHIOS data show mean immunoglobulin G (IgG) levels in people treated with Kesimptaremained unchanged over 3.5 years and mean immunoglobulin M (IgM) levels remained within the reference range1
Lower serum immunoglobulin levels, known to occur with other anti-CD20 therapies in MS patients, have been linked to an increased risk of infection, while immunoglobulin data with Kesimpta showed no association with risk of serious infections1, 2, 3
Data plan for the ALITHIOS sub-study on antibody-mediated immunity post-vaccination in Kesimpta-treated patients will be presented; data generated will provide greater understanding of how the B-cell depleting treatment will impact immune response to vaccinations1
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS4
Basel, June 22, 2021 — Today, Novartis disclosed new data showing mean IgG and IgM levels remain unchanged in adults with relapsing multiple sclerosis (RMS) treated with Kesimpta® (ofatumumab) over 3.5 years. The ongoing open label extension of the ALITHIOS study includes 1,703 people living with MS taking Kesimpta for up to 5 years. At the time of analysis, 456 of these people had reached 3.5 years of Kesimpta treatment duration. The long-term findings were consistent with the Phase III ASCLEPIOS trials data, which demonstrated that the overall incidence of infections was low, and no association was observed between decreased immunoglobulin levels and the risk of serious infections1. These data reinforce Kesimpta as a well-tolerated treatment option for people living with RMS.
“Evidence shows that low immunoglobulin levels have been linked to an increased risk of infection, which is why testing of these levels is recommended for people living with MS prior to taking any anti-CD20 treatment,” said Professor Heinz Wiendl, Director of the Clinic of Neurology at UKM Münste. “It’s encouraging to see that over a long period of time, IgG levels remained stable and IgM levels remained well within the reference ranges in all groups treated with ofatumumab, with no increased risk of infections.”
The results will be presented at the 7th Congress of the European Academy of Neurology – Virtual 2021, together with other wide-ranging data to further the understanding of how Kesimpta might impact immune response to a variety of standard vaccinations.
“Patient safety is of the utmost importance to Novartis and these long-term results continue to support Kesimpta as a high-efficacy, first-choice treatment with a favorable safety profile for people living with RMS,” said Marcia Kayath, Global Head Medical Affairs, Novartis Pharmaceuticals. “Preservation of immunoglobulin levels is important to fight infections, like COVID-19, so we’re very happy to share long-term data showing Kesimpta had unchanged IgG levels, providing physicians with important information relevant to the long-term benefit/risk of treating with Kesimpta.”
Disclaimer This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
About Novartis Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Jasińska E, Habek M, Wynnet D, et al. Impact of Ofatumumab on Immune Responses Post-vaccination in RMS Patients: ALITHIOS Vaccination Sub-study Design. Oral presentation at: EAN 2021; June 19-22, 2021.
Furst D. Serum immunoglobulins and risk of infection: how low can you go? Seminars in Arthritis and Rheumatism. 2009;39(1):18-29.
Tallantyre E, Whittam D, Jolles S, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265(5):1115–1122.
Hauser S, Bar-Or A, Cohen J, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2020;383(6):546-557.